... WhatsApp

Second-Line Treatments for Advanced Stomach Cancer Show Similar Results

You are here >> Home > Latest Updates > Stomach Cancer > Second-Line…

Relative Clinical Efficacy and Safety of Second- or Later-Line Treatments for Advanced and Metastatic Gastric Cancer A Rapid Review and Network Meta-Analysis.

When stomach cancer spreads or returns after the first treatment, doctors often use second-line therapies to try to control the disease.

Many new medicines have been developed in recent years, but it has been unclear whether they work better than older treatments.

This study reviewed 44 clinical trials looking at different treatments used after the first therapy for advanced or metastatic gastric cancer.

Researchers compared several options recommended in international guidelines.
The results showed that most treatments worked similarly when it came to important outcomes like survival and how long the cancer stayed under control. No treatment clearly outperformed the others in these areas.
One difference was seen with pembrolizumab, an immunotherapy drug. Patients receiving pembrolizumab had fewer serious treatment-related side effects compared with those receiving the chemotherapy drug paclitaxel.
Overall, the study shows that while the number of treatment options is growing, many second-line treatments currently offer similar benefits and risks. Doctors often choose a therapy based on the patient’s health, prior treatments, and potential side effects.
Researchers say there is still a strong need for new treatments that can improve survival and safety for patients with advanced stomach cancer.

Rate this post
Dr. Harsh J Shah
Dr Harsh Shah - GI & HPB Oncosurgeon in India
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.